S&P 500   4,089.11 (+0.94%)
DOW   33,133.18 (+0.83%)
QQQ   319.16 (+1.10%)
AAPL   163.96 (+0.99%)
MSFT   286.56 (+0.88%)
META   209.80 (+0.94%)
GOOGL   102.73 (+1.82%)
AMZN   102.98 (+0.96%)
TSLA   205.70 (+5.34%)
NVDA   277.33 (+1.28%)
NIO   10.49 (+0.29%)
BABA   102.28 (-1.06%)
AMD   97.47 (-0.42%)
T   19.17 (+0.47%)
F   12.43 (+1.14%)
MU   60.97 (-3.36%)
CGC   1.76 (-0.28%)
GE   95.12 (+1.14%)
DIS   99.29 (+1.21%)
AMC   4.91 (-1.21%)
PFE   40.37 (-0.02%)
PYPL   75.14 (+1.01%)
NFLX   342.97 (+1.34%)
S&P 500   4,089.11 (+0.94%)
DOW   33,133.18 (+0.83%)
QQQ   319.16 (+1.10%)
AAPL   163.96 (+0.99%)
MSFT   286.56 (+0.88%)
META   209.80 (+0.94%)
GOOGL   102.73 (+1.82%)
AMZN   102.98 (+0.96%)
TSLA   205.70 (+5.34%)
NVDA   277.33 (+1.28%)
NIO   10.49 (+0.29%)
BABA   102.28 (-1.06%)
AMD   97.47 (-0.42%)
T   19.17 (+0.47%)
F   12.43 (+1.14%)
MU   60.97 (-3.36%)
CGC   1.76 (-0.28%)
GE   95.12 (+1.14%)
DIS   99.29 (+1.21%)
AMC   4.91 (-1.21%)
PFE   40.37 (-0.02%)
PYPL   75.14 (+1.01%)
NFLX   342.97 (+1.34%)
S&P 500   4,089.11 (+0.94%)
DOW   33,133.18 (+0.83%)
QQQ   319.16 (+1.10%)
AAPL   163.96 (+0.99%)
MSFT   286.56 (+0.88%)
META   209.80 (+0.94%)
GOOGL   102.73 (+1.82%)
AMZN   102.98 (+0.96%)
TSLA   205.70 (+5.34%)
NVDA   277.33 (+1.28%)
NIO   10.49 (+0.29%)
BABA   102.28 (-1.06%)
AMD   97.47 (-0.42%)
T   19.17 (+0.47%)
F   12.43 (+1.14%)
MU   60.97 (-3.36%)
CGC   1.76 (-0.28%)
GE   95.12 (+1.14%)
DIS   99.29 (+1.21%)
AMC   4.91 (-1.21%)
PFE   40.37 (-0.02%)
PYPL   75.14 (+1.01%)
NFLX   342.97 (+1.34%)
S&P 500   4,089.11 (+0.94%)
DOW   33,133.18 (+0.83%)
QQQ   319.16 (+1.10%)
AAPL   163.96 (+0.99%)
MSFT   286.56 (+0.88%)
META   209.80 (+0.94%)
GOOGL   102.73 (+1.82%)
AMZN   102.98 (+0.96%)
TSLA   205.70 (+5.34%)
NVDA   277.33 (+1.28%)
NIO   10.49 (+0.29%)
BABA   102.28 (-1.06%)
AMD   97.47 (-0.42%)
T   19.17 (+0.47%)
F   12.43 (+1.14%)
MU   60.97 (-3.36%)
CGC   1.76 (-0.28%)
GE   95.12 (+1.14%)
DIS   99.29 (+1.21%)
AMC   4.91 (-1.21%)
PFE   40.37 (-0.02%)
PYPL   75.14 (+1.01%)
NFLX   342.97 (+1.34%)
NASDAQ:CHRS

Coherus BioSciences - CHRS Stock Forecast, Price & News

$6.78
+0.35 (+5.44%)
(As of 03/31/2023 01:57 PM ET)
Add
Compare
Today's Range
$6.51
$6.83
50-Day Range
$5.89
$9.18
52-Week Range
$5.58
$14.11
Volume
335,167 shs
Average Volume
1.13 million shs
Market Capitalization
$539.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

Coherus BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
144.4% Upside
$16.50 Price Target
Short Interest
Bearish
15.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.08
Upright™ Environmental Score
News Sentiment
0.46mentions of Coherus BioSciences in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.45) to $1.03 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

393rd out of 1,009 stocks

Biological Products, Except Diagnostic Industry

68th out of 166 stocks


CHRS stock logo

About Coherus BioSciences (NASDAQ:CHRS) Stock

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CHRS Stock News Headlines

UBS Upgrades Coherus Biosciences (CHRS)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
6 analyst picks: Lululemon sparkles | Pro Recap
Unusual Passive Income Investment (Found on a Golf Course)
Marc reveals how anyone can get into a similar opportunity for just $5.
Q4 2022 Coherus BioSciences Inc Earnings Call
FDA Approves UDENYCA® Autoinjector
Here's what Wall Street expects from Coherus BioSciences's earnings
CHRS.O - | Stock Price & Latest News | Reuters
See More Headlines
Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CHRS Company Calendar

Last Earnings
3/06/2023
Today
3/31/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CHRS
Fax
N/A
Employees
332
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$16.50
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+156.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-291,750,000.00
Net Margins
-138.24%
Pretax Margin
-138.24%

Debt

Sales & Book Value

Annual Sales
$211.04 million
Book Value
($1.77) per share

Miscellaneous

Free Float
70,128,000
Market Cap
$511.89 million
Optionable
Optionable
Beta
0.92

Social Links


Key Executives

  • Denny M. LanfearDenny M. Lanfear
    Chairman, President & Chief Executive Officer
  • McDavid StilwellMcDavid Stilwell
    Chief Financial Officer
  • Richard L. Hameister
    Chief Technical Officer
  • Rosh Dias
    Chief Medical Officer
  • Bryan Mcmichael
    Chief Accounting Officer, Senior VP & Controller













CHRS Stock - Frequently Asked Questions

Should I buy or sell Coherus BioSciences stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CHRS shares.
View CHRS analyst ratings
or view top-rated stocks.

What is Coherus BioSciences' stock price forecast for 2023?

5 analysts have issued 12 month target prices for Coherus BioSciences' shares. Their CHRS share price forecasts range from $11.00 to $26.00. On average, they predict the company's stock price to reach $16.50 in the next year. This suggests a possible upside of 156.6% from the stock's current price.
View analysts price targets for CHRS
or view top-rated stocks among Wall Street analysts.

How have CHRS shares performed in 2023?

Coherus BioSciences' stock was trading at $7.92 at the start of the year. Since then, CHRS shares have decreased by 18.8% and is now trading at $6.43.
View the best growth stocks for 2023 here
.

Are investors shorting Coherus BioSciences?

Coherus BioSciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 12,050,000 shares, an increase of 22.5% from the February 28th total of 9,840,000 shares. Based on an average daily volume of 1,260,000 shares, the short-interest ratio is presently 9.6 days.
View Coherus BioSciences' Short Interest
.

When is Coherus BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our CHRS earnings forecast
.

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) released its earnings results on Monday, March, 6th. The biotechnology company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.12. The biotechnology company had revenue of $45.35 million for the quarter, compared to the consensus estimate of $45.72 million. Coherus BioSciences had a negative trailing twelve-month return on equity of 422.10% and a negative net margin of 138.24%. During the same period in the prior year, the company earned ($0.60) EPS.

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (7.99%), Aristotle Capital Boston LLC (2.68%), Geode Capital Management LLC (1.62%), Peregrine Capital Management LLC (1.44%), Citigroup Inc. (0.99%) and Morgan Stanley (0.92%). Insiders that own company stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends
.

How do I buy shares of Coherus BioSciences?

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coherus BioSciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $6.43.

How much money does Coherus BioSciences make?

Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $511.89 million and generates $211.04 million in revenue each year. The biotechnology company earns $-291,750,000.00 in net income (profit) each year or ($3.76) on an earnings per share basis.

How many employees does Coherus BioSciences have?

The company employs 332 workers across the globe.

Does Coherus BioSciences have any subsidiaries?
The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..
Read More
How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for the company is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com.

This page (NASDAQ:CHRS) was last updated on 3/31/2023 by MarketBeat.com Staff